On SAVA's fourth-quarter 2024 earnings call, investors can expect updates regarding the company's pipeline developmental plans amid recent setbacks.

Cassava Sciences, Inc. engages in the development of novel drugs and diagnostics. It focuses on developing product candidates intended for the treatment of Alzheimer’s disease, including PTI-125 ...

07, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a clinical-stage biotechnology company focused on Simufilam did not show a significant ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Based on 3 Wall Street analysts offering 12 month price targets forCassava Sciences Inc - Dist in the last 3 months.

After hours: 7:58:39 p.m. EST ...

Cassava Sciences Price Performance Shares of NASDAQ SAVA opened at $2.42 on Friday. The stock has a market capitalization of $116.43 million, a PE ratio of -1.75 and a beta of -0.95. Cassava ...

Cassava Sciences' troubled development of Alzheimer's disease candidate simufilam looks like it may have finally reached the end. The Austin, Texas-based biotech revealed that simufilam failed its ...